GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results

         GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results

  PR Newswire

  LONDON, April 24, 2013

LONDON, April 24, 2013 /PRNewswire/ --

GlaxoSmithKline reported a 2% decline in Group revenues in line with
expectations and a dividend increase of 6% as part of its 2013 Q1 results. The
pharmaceutical giant also officially announced the divestment of Lucozade and
Ribena as well as the creation of a 'Global Established Products' group within
its portfolio that would get a different strategic focus from the more
innovative products.

In a video interview, Chief Financial Officer Simon Dingemans said he felt
"very comfortable" about the trends the group was seeing from its performance
with strong results from Japan and the US offsetting the tougher European
environment.

He emphasized his confidence that the Group was on track to deliver the
guidance of 3 to 4% earnings growth in constant currency terms, on sales
growth of around 1%. He also highlighted the "significant, continued progress"
GSK was making in the pipeline with six new products that had been "called out
in front of regulators on both sides of the Atlantic".

The video interview and transcript are available to watch now for free at
http://video.merchantcantos.com .

MerchantCantos produces in-depth interviews, documentaries and webcasts with
senior company executives. If you would like to contact us, please email
prnsupport@merchantcantos.com or phone +44-207-936-1352.
 
Press spacebar to pause and continue. Press esc to stop.